Baker Bros. Advisors LP Aeglea Bio Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $6.81 Million - $9.53 Million	-969,486 Reduced 22.14%	3,410,106 $26.8 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $10.7 Million - $29.4 Million	2,665,988 Added 155.58%	4,379,592 $40.5 Million
Q4 2018 Feb 13, 2019	BUY	$6.51 - $10.19 $2.12 Million - $3.32 Million	325,732 Added 23.47%	1,713,604 $12.8 Million
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $1.97 Million - $2.72 Million	250,000 Added 21.97%	1,387,872 $14.7 Million
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.93 $3.31 Million - $5.61 Million	1,137,872	1,137,872 $5.61 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.